Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.
MADISON – Nautilus Diner manager and borough resident Irvin Artavia used the Heimlich maneuver to save a customer from choking Thursday, Jan. 4.
/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on Jan. 26, 2024...
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr
/PRNewswire/ -- DelveInsight's Global mRNA-based Vaccines and Therapeutics Market Insights report includes a comprehensive understanding of current treatment...